Dr. Liao is a medical oncologist who specializes in hepatobiliary cancers and neuroendocrine tumors. He serves as the Medical Director of UChicago Medicine’s Hematology/Oncology clinic, the Interim Director of Gastrointestinal Oncology Program, and the Co-Director of the Neuroendocrine Tumor Program. He is a prolific clinical researcher and has served as the principal investigator of more than 60 clinical trials involving novel systemic therapies for hepatobiliary cancers, neuroendocrine tumors and thyroid cancer, leading to numerous publications in peer-reviewed medical journals. He is also a dedicated mentor in clinical education and research for medical students, residents and fellows.
Washington University in St. Louis
St. Louis, MO
- Hematology/Oncology Fellowship
2017
Rush University Medical Center
Chicago, IL
- Internal Medicine Residency
2014
Vanderbilt University School of Medicine
Nashville, TN
MD - Medicine
2011
University of California, Berkeley
Berkeley, CA
BA - Molecular & Cell Biology -- Genetics
2006
Survival Outcomes of Radiofrequency Ablation for Intrahepatic Cholangiocarcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database: Comparison with Radiotherapy and Resection.
Survival Outcomes of Radiofrequency Ablation for Intrahepatic Cholangiocarcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database: Comparison with Radiotherapy and Resection. J Vasc Interv Radiol. 2025 03; 36(3):489-498.e3.
PMID: 39491643
The Changing Demographics and Epidemiology of Hepatocellular Carcinoma.
The Changing Demographics and Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis. 2025 Feb; 29(1):1-15.
PMID: 39608950
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors.
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2025 01; 177:108834.
PMID: 39395860
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
PMID: 39093924
Targeted therapies in hepatocellular carcinoma: past, present, and future.
Targeted therapies in hepatocellular carcinoma: past, present, and future. Front Oncol. 2024; 14:1432423.
PMID: 39267840
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors.
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. Cancers (Basel). 2024 Aug 28; 16(17).
PMID: 39272851
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers.
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol. 2024 May; 8:e2300531.
PMID: 38723230
Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors.
Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 07; 35(7):989-997.e2.
PMID: 38490364
Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma.
Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024 Apr; 34(4):2374-2383.
PMID: 37812295
Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.
Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility. J Interv Med. 2023 Nov; 6(4):187-193.
PMID: 38312131